drugset / Trial / NCT02102633

Drug Interaction Study Between Bosutinib And Dabigatran

NCT02102633

Phase 1 Completed 27 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

The study evaluates the effect of a single oral dose of bosutinib on the single dose pharmacokinetics of dabigatran, a p-glycoprotein substrate, in healthy subjects.

Timeline

Start
2014-05
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosutinib Small molecule 500 mg Oral
Subject Dabigatran Unknown 150 mg Oral

Indications

No indication recorded.